TABLE 3

Factors associated with completion of preventive treatment

Preventive treatment completionUnivariableMultivariable
NoYes#OR (95% CI)p-valueaOR (95% CI)p-value
Total409723 634 (85)
Period
 1993–19967184812 (87)0.77 (0.68–0.87)<0.0011.0 (0.86–1.2)0.84
 1997–200010195080 (83)0.57 (0.51–0.64)<0.0010.77 (0.65–0.90)0.001
 2001–200410754898 (82)0.52 (0.47–0.59)<0.0010.74 (0.63–0.87)<0.001
 2005–20087764420 (85)0.66 (0.58–0.74)<0.0010.79 (0.67–0.92)0.002
 2009–20135094424 (90)1.01.0
Age group years
 0–142222858 (93)1.01.0
 15–2410757471 (87)0.54 (0.46–0.63)<0.0010.53 (0.45–0.61)<0.001
 25–3410685817 (84)0.42 (0.36–0.49)<0.0010.40 (0.35–0.47)<0.001
 35–449274129 (82)0.35 (0.30–0.40)<0.0010.33 (0.28–0.39)<0.001
 45–546302461 (80)0.30 (0.26–0.36)<0.0010.28 (0.24–0.33)<0.001
 55–64143717 (83)0.39 (0.31–0.49)<0.0010.30 (0.24–0.38)<0.001
 ≥6532181 (85)0.44 (0.29–0.66)<0.0010.31 (0.20–0.47)<0.001
Sex
 Male195611 634 (86)1.01.0
 Female213911 981 (85)0.94 (0.88–1.0)0.070.93 (0.87–0.99)0.03
Origin
 Foreign born6563817 (85)1.00.831.0
 Dutch born340819 646 (85)0.99 (0.90–1.1)0.811.2 (1.0–1.3)0.01
 Unknown33171 (84)0.89 (0.61–1.3)0.551.0 (0.70–1.5)0.84
Residence
 Urban9815393 (85)1.01.0
 Rural311618 241 (85)1.1 (0.99–1.2)0.111.1 (1.0–1.2)0.05
BCG vaccination
 No BCG355920 226 (85)1.00.04
 BCG3262162 (87)1.2 (1.0–1.3)0.01
 Unknown2121246 (85)1.0 (0.89–1.2)0.62
Diagnostic test
 TST8945788 (87)1.0
 IGRA54368 (87)1.1 (0.78–1.4)0.73
 TST and IGRA3152582 (89)1.3 (1.1–1.5)0.001
 Unknown283414 896 (84)0.81 (0.75–0.88)<0.001
Target group
 TB contact258814 972 (85)1.01.0
 Immunosuppression92628 (87)1.2 (0.94–1.5)0.151.5 (1.2–1.9)0.001
 Pre-exposure examination6914140 (86)1.0 (0.95–1.1)0.451.0 (0.92–1.1)0.87
 Professional at risk36348 (91)1.7 (1.2–2.4)0.0041.6 (1.1–2.2)0.01
 Traveller41511 (93)2.2 (1.6–3.0)<0.0011.79 (1.3–2.5)<0.001
 Other post-exposure6412933 (82)0.79 (0.72–0.87)<0.0010.83 (0.75–0.92)<0.001
 Fibrotic lesions8102 (93)2.2 (1.1–4.50.034.4 (2.1–9.2)<0.001
Preventive treatment regimen
 6–9 months isoniazid341819 423 (85)1.01.0
 4 months rifampicin65667 (91)1.8 (1.4–2.3)<0.0011.7 (1.3–2.2)<0.001
 3–4 months rifampicin/isoniazid2692896 (92)1.9 (1.7–2.2)<0.0011.7 (1.4–2.0)<0.001
 Other or unknown345648 (65)0.33 (0.29–0.38)<0.0010.35 (0.30–0.40)<0.001
  • Data are presented as n or n (%), unless otherwise stated. OR: odds ratio; aOR: adjusted OR; BCG: bacille Calmette–Guerin; TST: tuberculin skin test; IGRA: interferon-γ release assay; TB: tuberculosis. #: percentage completed of row total given in parentheses; : post-exposure.